Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
Fecha
2020Autor
Chen, Xiangyu
Pan, Zhiwei
Yue, Shuai
Yu, Fei
Zhang, Junsong
Yang, Yang
Li, Ren
Liu, Bingfeng
Yang, Xiaofan
Gao, Leiqiong
Li, Zhirong
Lin, Yao
Huang, Qizhao
Xu, Lifan
Tang, Jianfang
Hu, Li
Zhao, Jing
Liu, Pinghuang
Zhang, Guozhong
Chen, Yaokai
Deng, Kai
Ye, Lilin
Resumen
COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation
between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of
59 recovered patients with disease severity including severe, moderate, mild, and asymptomatic, we observed the positive
correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the
patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the
compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-tomoderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their
correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from
asymptomatic or mild illness.
Palabras clave
SARS-CoV-2-specific; Disease severity dictates; COVID-19Enlace al recurso
https://doi.org/10.1038/s41392-020-00301-9Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.